- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1b/2 Open-Label Study of Samuraciclib in Combination with Elacestrant in Participants with Metastatic or Locally Advanced Hormone-Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
This study looks at combining two drugs, samuraciclib and elacestrant, for people with advanced breast cancer. It aims to find the best dose and see how well the combination works and if it's safe.
For: Breast CancerFrance · Spain - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
C4891024 - TACTIVE-U: AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT (ARV-471/PF-07850327), AN ORAL PROTEOLYSIS TARGETING CHIMERA, IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS AGED 18 AND OLDER WITH ER+ ADVANCED OR METASTATIC BREAST CANCER, SUB-STUDY C (ARV-471 IN COMBINATION WITH SAMURACICLIB)
This study is testing a new combination treatment for advanced or metastatic breast cancer. It combines a drug called vepdegestrant (ARV-471) with samuraciclib. Researchers are looking at how safe and effective this new combination is for people aged 18 and over.
For: Advanced or Metastatic Breast CancerItaly · Spain · France